Τίτλος:
Patients with inflammatory bowel disease are not at increased risk of covid-19: A large multinational cohort study
Γλώσσες Τεκμηρίου:
Αγγλικά
Περίληψη:
The impact of COVID-19 on inflammatory bowel disease (IBD) patients under pharmacological immunosuppression is still not clearly understood. We investigated the incidence of COVID-19 and the impact of immunosuppression and containment measures on the risk of SARS-CoV-2 infection in a large IBD cohort, from a multicenter cohort from 21st of February to 30th of June, 2020. Ninety-seven patients with IBD (43 UC, 53 CD, one unclassified IBD) and concomitant COVID-19 over a total of 23,879 patients with IBD were enrolled in the study. The cumulative incidence of SARS-CoV-2 infection in patients with IBD vs. the general population was 0.406% and 0.402% cases, respectively. Twenty-three patients (24%) were hospitalized, 21 (22%) had pneumonia, four (4%) were admitted to the Intensive Care Unit, and one patient died. Lethality in our cohort was 1% compared to 9% in the general population. At multivariable analysis, age > 65 years was associated with increased risk of pneumonia and hospitalization (OR 11.6, 95% CI 2.18–62.60; OR 5.1, 95% CI 1.10–23.86, respectively), treatment with corticosteroids increased the risk of hospitalization (OR 7.6, 95% CI 1.48–40.05), whereas monoclonal antibodies were associated with reduced risk of pneumonia and hospitalization (OR 0.1, 95% CI 0.04–0.52; OR 0.3, 95% CI 0.10–0.90, respectively). The risk of COVID-19 in patients with IBD is similar to the general population. National lockdown was effective in preventing infection in our cohort. Advanced age and treatment with corticosteroids impacted negatively on the outcome of COVID-19, whereas monoclonal antibodies did not seem to have a detrimental effect. © 2020 by the authors. Licensee MDPI, Basel, Switzerland.
Συγγραφείς:
Allocca, M.
Chaparro, M.
Gonzalez, H.A.
Bosca-Watts, M.M.
Palmela, C.
D’amico, F.
Zacharopoulou, E.
Kopylov, U.
Ellul, P.
Bamias, G.
Ntelis, V.
Lahat, A.
Mantzaris, G.J.
Papaconstantinou, I.
Katsanos, K.
Uspenskaya, Y.
Christodoulou, D.
Horin, S.B.
Peyrin-Biroulet, L.
Torres, J.
Sebastian, S.
Gisbert, J.P.
Danese, S.
Fiorino, G.
Περιοδικό:
Journal of Clinical Medicine Research
Λέξεις-κλειδιά:
agents used in inflammatory bowel disease; azathioprine; corticosteroid; cytokine receptor antagonist; filgotinib; immunosuppressive agent; infliximab; interleukin 12 blocking agent; interleukin 23 blocking agent; Janus kinase inhibitor; methotrexate; monoclonal antibody; tacrolimus; tumor necrosis factor inhibitor; unclassified drug; vedolizumab, adult; aged; Article; cohort analysis; combination drug therapy; comparative study; controlled clinical trial; controlled study; coronavirus disease 2019; corticosteroid therapy; Crohn disease; death; female; hospital admission; hospitalization; human; immunosuppressive treatment; incidence; infection control; infection risk; inflammatory bowel disease; intensive care unit; lethality; major clinical study; male; multicenter study; nose smear; observational study; polymerase chain reaction; population; pregnant woman; prospective study; risk reduction; throat culture; virus pneumonia
